Key Points
- CEO Jennifer Buell sold 6,938 shares of MiNK Therapeutics at an average price of $10.56, totaling $73,265.28. The sale, which covered tax withholding tied to vested equity awards, reduced her ownership by 8.55% to 74,195 shares.
- MiNK Therapeutics shares opened at $10.35, compared with 50-day and 200-day moving averages of $11.60 and $11.47, respectively, and have traded between $8.48 and $16.93 over the past year.
- The company reported a quarterly loss of $0.62 per share, missing the $0.60 consensus estimate. Analysts’ overall rating is Hold, with one Buy, one Hold, and one Sell rating, and a consensus price target of $35.00.
MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) CEO Jennifer Buell sold 6,938 shares of MiNK Therapeutics stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $10.56, for a total transaction of $73,265.28. Following the sale, the chief executive officer owned 74,195 shares of the company's stock, valued at approximately $783,499.20. This trade represents a 8.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
MiNK Therapeutics Price Performance
NASDAQ:INKT opened at $10.35 on Thursday. The firm has a 50 day simple moving average of $11.60 and a 200-day simple moving average of $11.47. MiNK Therapeutics, Inc. has a 1-year low of $8.48 and a 1-year high of $16.93.
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02). As a group, research analysts expect that MiNK Therapeutics, Inc. will post -1.93 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on INKT. Weiss Ratings reiterated a "sell (d-)" rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Zacks Research cut MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $35.00.
Read Our Latest Stock Analysis on MiNK Therapeutics
MiNK Therapeutics Company Profile
(
Get Free Report)
MiNK Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company's research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.
MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.
The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
